Ryvu Therapeutics S.A. is a Polish biotechnology company based in Krakow, dedicated to the scientific research and development of new anti-cancer therapies. Their primary focus is on addressing severe conditions such as acute myeloid leukemia (AML), high-risk and low-risk myelodysplastic syndromes (HR-MDS, LR-MDS), bone marrow fibrosis (myelofibrosis), and diffuse large B-cell lymphoma (DLBCL). To accelerate the development of these crucial therapies, Ryvu Therapeutics S.A. actively engages in collaborations with international research centers and pharmaceutical companies. Their clinical trials span across multiple countries, including Poland, Germany, France, Spain, Italy, as well States, and Canada, demonstrating a broad global reach in their research efforts.